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1 Introduction
Advance in genome research has provided 
tools such as DNA microarrays that can be used 
to analyze the expression and suppression stage 
in several genes at once. This revealed the fact 
that not all cells in vivo are expressing the same 
genes in the same manner, but that each cell 
shows a specific pattern of gene expression. For 
example, a skin cell and a liver cell each express 
different genes. This implies the presence of in 
vivo mechanisms for controlling gene expression.
In cancer cells found in cancer-developing 
tissues or organs, genes that are suppressed in 
normal cells are expressed while those expressed 
in normal cells are suppressed, implying the 
involvement of abnormal gene expression in 
cancer development. In addition to cancer, 
abnormal expression or suppression of genes is 
involved in many lifestyle-related diseases such as 
diabetes.
Research on mechanisms of gene expression 
and suppression are showing remarkable growth. 
Such areas include “gene - silencing research,” 
which involves study of the mechanism of gene 
suppression without genetic change (mutation) in 
the genomic DNA itself.
As shown in Table 1, various subjects are 
studied in gene-silencing research, such as DNA 
methylation, chromatin modification, structural 
change in chromosomes and RNA-mediated 
s u p p r e s s i o n  o f  g e n e  e x p r e s s i o n  ( R N A  
interference)[1].
Gene suppression mechanism research is 
active, because the development of techniques 
for controlling gene expression will lead to the 
development of new drugs for treating various 
diseases.
Nucleic acid compounds are chemical ly 
synthesized and introduced into cells to suppress 
gene express ion th rough s toich iometr ic  
inhibition of gene transcription or translation. 
Typical examples of such nucleic acids are 
single-stranded synthetic DNAs or RNAs and RNA 
enzymes (ribozymes). Small double - stranded 
RNAs are attracting attention for their stability 
and high efficacy in gene suppression.
Unl ike conventional synthesized nucleic 
acid compounds, small double -stranded RNAs 
suppress gene expression employing a biological 
mechanism which all organisms retain. This 
report triggered the advance in gene suppression 
mechanism research and facilitated the expansion 
of gene-silencing research.
T h i s  r e p o r t  d e s c r i b e s  t h e  t r e n d s  i n  
gene - silencing research with the focus being 
on research on the small double-stranded RNA 
mechanism, and further discusses the potential of 
gene-silencing research for drug development. In 
addition, this paper describes various strategies 
for further development in this area.
Table1 : Subjects studied in gene silencing research area
Research target Research subjects
Mechanism of gene suppression 
without genetic change in the 
genomic DNA itself
DNA methylation, 
chromatin modification, 
structural change in chromosomes,  RNA interference (RNAi), siRNA,  suppression of gene 
expression mediated by synthetic nucleic acid compounds
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2 The history of gene-silencing
 research (years 1990-2001)
The present section covers the gene-silencing 
research (basic research) conducted since the 
phenomenon was first reported in 1990 until 
2001 and introduces breakthrough studies in this 
area.
2-1 Gene-silencing research originated
 from studies of plants
The suppression of gene expression called 
“gene silencing” was first reported in 1990 in 
studies of plants[2,3].
The phenomenon was discovered almost by 
coincidence, when the transformation of petunias 
with transgenes involved in purple pigmentation 
for artificially producing dark-colored flowers 
unexpectedly resulted in white flowers. It was 
considered that the overexpression of transgenes 
had suppressed the expression of the endogenous 
pigment genes.
Subsequent research on the mechanism of gene 
silencing suggests that the phenomenon were not 
induced by DNA suppression but rather by RNA 
suppression.
2-2 Gene-silencing research concerning
 double-stranded RNA started
 in nematodes
The suppression of gene expression by the 
introduction of exogenous single-stranded RNAs 
into cells was first reported in 1985[4], but it was 
not until 1988 that double-stranded RNAs were 
found to be directly involved in gene suppression.
The introduction of large (300kbp or larger) 
double-stranded RNAs into the cells of nematodes 
suppressed gene expression more selectively and 
efficiently than in the case of single - stranded 
RNAs[5,6].
The suppression of gene expression by 
double - st randed R NAs was named “R NA i 
(RNA interference)” and has been reported in 
invertebrates such as hydra, drosophila and 
plants.
Single-stranded RNAs suppress gene expression 
by binding to target mRNAs and mechanically 
inhibit ing thei r translat ion into proteins. 
Double-stranded RNAs suppress gene expression 
using a gene-silencing mechanism that originally 
existed in vivo but has recently been discover. 
The mechanism is explained in Section 2-5.
2-3 Discovery of small RNAs as performers
 of gene silencing
Large double-stranded RNAs introduced into 
plant or nematode cells are broken down into 
small double-stranded RNAs of about 22bp within 
cells. These small double-stranded RNAs induce 
gene silencing, which was demonstrated in a 
series of reports published in 1999-2000.
I n  20 01,  a n  en z y me decompos i ng  t he  
double - stranded RNAs was discovered from 
drosophila and was named “Dicer”[7], which was 
also later discovered in mammalian cells[8].
The discovery of this enzyme suggests that gene 
suppression by double-stranded RNAs is a common 
phenomenon found in all organisms. The next step 
was to search for the small double-stranded RNAs 
that actually function in cells.
2-4 Introduction of double-stranded RNAs
 also induced gene silencing in mammals
Because the mammal ian mechanism for 
gene s i lencing i s  d i f ferent f rom those in 
plants or invertebrates such as nematodes, it 
is considered that gene suppression mediated 
by double - stranded RNA is not applicable to 
mammalian cells. When long double - stranded 
RNAs of 30 bp or larger are introduced into 
mammalian cells, the cells mistake it for virus 
invasion and release interferon, ultimately 
inducing cell death instead of gene suppression.
Based on the results of gene-silencing studies 
conducted in nematodes and plants, smal l 
double-stranded RNAs of the same size (21 bp) 
as those decomposed by Dicer, were introduced 
into mammal ian cel ls instead of the large 
double-stranded RNAs. This attempt succeeded 
in inducing gene silencing in various cultured 
mammalian cells, including human cells, without 
causing cell death[9].
This discovery was a breakthrough in the 
use of double-stranded RNA in mammals. Small 
double-stranded RNAs (small interference RNA, 
siRNA) has rapidly drawn attention as a universal 
tool for suppressing gene expression.
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2-5 Mechanism of gene silencing mediated
 by double-stranded RNAs
Figure 1 illustrates the mechanism of gene 
silencing mediated by double-stranded RNAs. This 
is considered a universal mechanism commonly 
found among all organisms including mammals.
(1)  Dicer cuts double-stranded RNA that enter 
cells into small fragments of about 22 bp to 
form small interference RNAs (siRNAs).
(2)  One of the two strands of the siRNA binds 
to a RISC (RNA-induced silencing) complex, 
while the other is decomposed.
(3)  The RNA - bound RISC complex binds 
to a messenger RNA having a sequence 
complementary to the RNA strand and 
decomposes the complementary region, 
result ing in the inhibit ion of protein 
synthesis.
2-6 Small RNAs involved in the regulation of
 in vivo gene expression
Several small RNAs are present within the 
cells and are involved in the regulation of gene 
expression.
These short double-stranded RNAs of 18-25 bp, 
called miRNAs (micro RNAs), were first reported 
in 2001[10]. RNAs (pseudodouble-stranded RNA) 
having hairpin secondary structures are cut by 
Dicer to form miRNAs. miRNAs consist of mRNA 
portions corresponding to non-translated regions.
The miRNA suppresses gene expression 
through a mechanism similar to that of siRNA, 
but unl ike siRNA, which completely binds 
to the target mRNA sequence, miRNA only 
partially binds to the target mRNA, resulting 
in no decomposition of mRNA. Therefore, 
miRNA is considered to inhibit protein synthesis 
stoichiometr ical ly. Moreover, since miRNA 
binds to the non-translated region within the 
mRNA sequence, it is believed that miRNA acts 
by binding to a region involved in the control of 
gene expression.
Hundreds of miRNAs can be found within 
a nematode or plant cell and are reported to 
be controlling the timing of development or 
regulation of stem cel ls. It is assumed that 
200 -250 miRNAs are present within human 
cells[11], and their functions have been actively 
researched.
Table 2 chronologically lists breakthrough 
studies in gene-silencing research. As can be seen, 
Figure 1 : Mechanism of gene silencing mediated
 by double-stranded RNAs
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Table 2 : Breakthrough studies in the area of gene silencing research (basic research)
Year Content Research target Highlights
1990 Suppression of flower color gene through gene transfer Plant
Discovery of modification in phenotypic 
traits through gene transfer
1998
Gene suppression mediated by double-stranded RNAs 
(siRNAs)
Nematode
Discovery of a novel gene suppression 
technique
2001
Discovery of an enzyme (Dicer) decomposing 
double-stranded RNAs (siRNAs) in vivo
Drosophila
Elucidation of gene suppression 
mechanism
2001
Gene suppression in mammalian cells by small 
double-stranded RNAs
Mammal
Discovery of a gene suppression 
technique for mammalian cells
2001
Discovery of small double-stranded RNAs (miRNAs) 
considered to be involved in the regulation of gene 
expression
Mammal
Discovery of a molecule essential to in 
vivo regulation of gene expression
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much of the research was performed in 2001.
3 Overview gene silencing
Based on its own database of research papers 
called Essential Science Indicators, Thomson 
Scientific analyzes research papers concerning 
particular research areas. In December 2003, the 
company reported the results obtained from their 
analysis of gene silencing[12].
The present section provides an overview of 
gene silencing based on the report by Thomson 
Scientific as well as the results obtained from our 
own research using the ESI database.
3-1 International comparison of
 gene-silencing research
Thomson Scientific performed a search on 
papers published during 1993-2003 using “gene 
silencing” as the keyword and extracted 1,505 
papers written by 4,540 authors representing 898 
research institutes from 48 nations and published 
in 365 academic journals[12] (the papers were 
searched by keywords by abstracts and authors).
• The United States is leading
 the gene-silencing research
According to Thomson Scientific, the United 
States was ranked the highest (17,073 citations 
from 697 papers) for the total number of citations 
of gene-silencing related papers on a country 
basis, followed by the United Kingdom (6,374 
citations from 168 papers), Germany (3,166 
citations from 128 papers), France (2,460 citations 
from 117 papers) and Scotland (1,716 citations 
from 47 papers). Japan was ranked 12th, with 649 
citations from 111 papers[12].
•  The number of citations for Japanese
 papers are increasing
In order to compare the numbers of citations 
on a country basis for the last two years, a similar 
search was performed using the ESI database.
Figure 2 shows the number of citations of 
papers published during the last two years 
(2002 -2003) for various countries. As in the 
analysis performed on years 1993-2003, the U.S. 
had the largest total number of citations for the 
last two years.
The total number of citations for Japanese 
papers increased to a  level  substant ia l ly  
equivalent to that of Germany or the U.K. 
Furthermore, about 70% of the papers published 
during 1993-2003 were published within these 
two years. This indicates that it has not been 
long since the research area has become active in 
Japan.
Figure 2 : Comparison of total numbers of citations of papers in gene silencing research area
  between countries (2002-2003)
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3-2 Characteristics of gene-silencing research
The characteristics of gene silencing were 
analyzed based on the ESI database.
•  Gene-silencing research is a multidiscipline
 area
The papers concerning gene-silencing research 
are classified by the academic area of the journals 
in which they are published. As a result, 35% 
of the papers fall under Molecular Biology & 
Genetics, while 21%, 19% and 13% fell under 
Plant & Animal Science, Biology & Biochemistry 
and Clinical Medicine, respectively[12] (Figure 3).
The analysis indicates that many academic areas 
are involved in the gene silencing.
•  The two major subjects dealt with
 in the ten most-cited papers were DNA
 methylation and RNAi
Table 3 lists the ten most-cited papers in gene 
silencing. The classification of these papers by 
their research subjects reveals the presence of 
two major subjects.
One is the mechanism of RNA - mediated 
gene silencing and the other is the mechanism 
of gene silencing mediated by DNA or histone 
methylation found in mammalian cells.
3-3 Shift in gene silencing research
Temporal changes in gene si lencing were 
revealed by analyzing the number of papers using 
Figure 3 : Classification of papers in gene silencing
  research by academic area
Table 3 : Ten most-cited papers
Number 
of citation
Titles Subjects
Authors
(Nationalities)
Journals 
(Years of publication)
1 913
Methylation-specific PCR: A novel PCR 
assay for methylation status of CpG 
islands STATUS OF CPG.
Methylation
Herma, JG et al. 
(U.S.)
PNANS (1996)
2 627
Duplexes of 21-nucleotide RNAs 
mediate RNA interference in cultured 
mammalian cells.
RNAi
Elbashir, SM 
(Germany)
NATURE (2001)
3 584
Methylated DNA and MECP2 recruit 
histone deacetylase to repress 
transcription.
Methylation
Jones, PL (U.S, 
Belgium, Italy)
NATURE GENETICS 
(1998)
4 522 Cancer epigenetics comes of age Epigenetic Jones, PA (U.S.)
NATURE GENETICS 
(1999)
5 411
Methylation of the 5’-CpG island of the 
P16/CDKN2 tumor-suppressor gene in 
normal and transformed human tissues 
correlates with gene silencing.
Methylation
Gonzalezzulueta, 
M (U.S.)
CANCER RESEARCH 
(1995)
6 345
A species of small antisense RNA in 
posttranscriptional gene silencing in 
plants.
Antisense 
RNA
Hamilton, AJ 
(U.K.)
SCIENCE (1999)
7 339
Selective recognition of methylated 
lysine 9 on histone H3 by the HP1 
chromo domain.
Methylation
Bannister, AJ 
(U.K., Scotland)
NATURE (2001)
8 308
Methylation of histone H3 lysine 9 
creates a binding site for HP1 proteins.
Methylation
Lachner, M 
(Austria)
NATURE (2001)
9 293
An RNA-directed nuclease mediates 
post-transcriptional gene silencing in 
Drosophila cells.
RNAi
Hammond, SM 
(U.S., U.K.)
NATURE (2000)
10 264
RNA interference is mediated by 21-and 
22-nucleotide RNAs.
RNAi
Elbashir, SM 
(Germany)
GENES & 
DEVELOPMENT (2001)
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the ESI database.
The number of papers published in each 
year was investigated using “gene silencing” 
as the search keyword. Only 31 papers were 
published in 1996, but the number of papers has 
continuously increased since then and drastically 
increased since 2001 (Figure 4).
In addition, as mentioned in Section 3 -2, 
since “RNA” and “methylation” were the major 
subjects researched in the most-cited papers in 
the gene-silencing research, these keywords were 
each combined with “gene silencing” to examine 
the temporal shift in research subjects within the 
area (Figure 4).
The result demonstrates that the mainstream 
has shifted from methylation to RNA research; 
the former was dominant until 1997 while the 
latter became dominant after 2002. This reflects 
the shift of researchers’ interest into small 
double-stranded RNAs after the mechanism for 
RNA-mediated gene silencing was fundamentally 
understood by 2001.
Furthermore, many reports suggesting the 
mutual involvement of “RNA” and “methylation” 
i n  t he  gene - s i l enc i ng  mech a n i sm we r e  
successively published in 2004[13 -15]. Therefore, 
the two subjects that were dealt with separately 
are likely to be integrated into a single research 
area.
4 Development of applied
 research on gene silencing
 toward disease therapy
 (2002-2004)
Experiments using mammalian cells or mice 
have been conducted in expectation of the 
development of new drugs and therapeutic or 
prevention methods using the small interference 
RNAs (siRNAs)[16]. The target candidates are 
diseases that are potentially cured by suppressing 
gene expression, such as virus diseases (e.g. 
HIV/AIDS, inf luenza, SARS, virus hepatitis), 
neurologic diseases (e.g. Parkinson’s disease, 
Alzheimer disease), cancer and autoimmune 
diseases (e.g. rheumatism).
Table 4 lists the breakthrough studies that 
contributed to the development of such applied 
studies.
4-1 Research on disease therapy
 by gene silencing
The following cases are examples of applied 
research on gene silencing performed using 
animal models for human diseases.
• Inhibition of HIV virus infection
In rapidly dividing cells, the absolute number 
Figure 4 : Shift in the number of papers and research subjects in the gene silencing research area (1996-2003)
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of siRNAs per cell decreases as the cells divide 
and propagate, so the effect of siRNA-mediated 
gene silencing only lasts for about 5 days. This 
was considered a drawback of siRNAs when using 
them as drugs, but research conducted in 2003 
provides a solution to this[20].
HIV viruses invade the macrophages by binding 
to CCR5 receptors present at the macrophage 
surface, so the inhibition of their binding to 
the receptors should prevent their infection. 
Moreover, macrophages do not undergo cell 
division, so siRNA-mediated gene suppression 
was expected to last over the long term.
siRNAs that suppress the expression of the 
macrophage CCR5 receptor genes and siRNAs 
that suppress the expression of HIV virus genes 
were produced and used in combination to 
test their effectiveness in preventing HIV virus 
infection.
The preliminary introduction of the siRNAs 
suppressing the CCR5 receptor gene expression 
into macrophages successfu l ly prevented 
HIV- infection of the macrophages. Moreover, 
siRNAs suppressing the expression of HIV 
virus genes proved effective for preventing the 
replication of viruses that have already infected 
the macrophages. These results demonstrate the 
potential of siRNAs, not only as preventive drugs 
but also as therapeutic drugs.
• Prevention of aggravation in liver diseases
Many l iver diseases are accompanied by 
apoptosis (cell death) in liver cells mediated by 
Fas protein. The death of liver cells deteriorates 
liver function, resulting in symptoms such as liver 
cirrhosis. Therefore, the prevention of cell death 
in liver cells by suppressing the expression of Fas 
protein should prevent the progression to severe 
status such as liver cirrhosis.
In 2003, siRNA-mediated gene silencing was 
reported in autoimmune hepatitis model mice. 
Development of hepatitis in the hepatitis model 
mice was successfully prevented by injecting 
siRNAs that contain sequences corresponding to 
the Fas gene via their tail veins[18].
4-2 Drug development research
 by gene silencing
Instead of being used as drugs, the small 
interference RNAs are used as tools for searching 
in vivo targets (proteins) for developing new 
drugs.
• Research on cancer drug development
In 2003,  de - ubiqu it i nat ing enz ymes in 
cancer-related pathways were identified using 
RNAi. The result demonstrates that the inhibition 
of familial cylindromatosis tumor suppressor gene 
(CYLD), having no known function, enhances the 
activation of the transcription factor NF-κB and 
imparts resistance to apoptosis (cell death)[21].
This implies that the loss of CYLD inhibits 
cell death and therefore inhibits the removal of 
abnormal cells, which leads to the accumulation 
of genetic mutations and develops cancer. 
Although the relationship between the loss of 
CYLD and oncogenesis has been recognized, the 
mechanism of CYLD-mediated oncogenesis is not 
understood.
Based on this research result, NF-κB inhibitors 
are researched as potential drugs for treating 
familial cylindromatosis.
4-3 Infrastructure development for promoting
 gene-silencing research
Databases concerning the small interference 
RNAs are established mainly in the U.S. and 
European countries to provide information such 
as RNAi sequence data.
Table 4 : Breakthrough studies in the area of gene silencing research (applied research)
Year Content Research target Highlights
2002
Gene suppression by injection of small 
double-stranded RNAs into mice through tail vein [17]
Mice
Successful in vivo delivery through an 
ordinary means
2003
Prevention of hepatitis using small double-stranded 
RNAs in hepatitis model mice [18]
Mice
Establishment of the principle for therapies 
mediated by small double-stranded RNAs
2004
Discovery of a novel molecule from a known 
signaling pathway through an RNAi-based 
screening system [19]
Human
Establishment of a large-scale screening 
system enabling search for novel targets 
for drug
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• Databases of small interference RNAs
 (miRNA)
The Br it ish Sanger Inst itute (funded by 
Wellcome Trust) has established a database 
of small interference RNAs[22,23]. To date, 899 
miRNAs have been registered, and data including 
78 drosophila, 166 nematode (two species) 
and 191 human miRNAs can be freely accessed 
(Figure 5).
4-4 Trends concerning drug development
Gene-silencing research has passed the applied 
research phase and now entered the phase of 
clinical studies and drug development.
•  Corporate-driven technical cooperation
 has been established for drug development
Many universit ies and companies forged 
technical partnership around 2003. Examples of 
such partnership are presented in the following 
section.
A U.S. company Sirna Therapeutics, Inc. 
entered into a l icense agreement with the 
University of Massachusetts Medical School 
concerning small interference RNA (siRNA) 
technology.
Merck & Co. Inc. and Alnylam Holding Co. 
collaborated to develop RNA-based technology 
and therapeutics. Alnylam Holding Co. is a 
merged company of Alnylam Pharmaceuticals 
Inc. and a German company Ribopharma AG. 
Ribopharma AG, who already had many European 
patents concerning RNAi, aimed at acquiring 
RNAi - related U.S. patents by merging with 
Alnylam Pharmaceuticals Inc.
Furthermore, Alnylam Pharmaceuticals Inc., 
the pharmaceutical division of the Alnylam 
Holding Co., formed a research collaboration 
with Mayo Clinic, the leading comprehensive 
medical institute in the U.S. functioning both as a 
general hospital and as a research and education 
institution, to develop therapeutic drugs for 
Parkinson’s disease using RNAi-based technology.
To date, no clinical study (clinical trial) such as 
human administration of siRNA drugs has been 
reported, but it is expected to begin in the near 
future (by the end of 2004 or 2005).
5 Unresolved research issues
 concerning gene-silencing
 research
The present section discusses the unresolved 
research issues for the medical application of 
gene silencing and suggests research required for 
their resolution.
5-1 Unresolved research issues
 in basic research
In gene-silencing research, many breakthrough 
studies at the basic research level were reported 
within a short period. This gives the impression 
that sufficient basic research has already been 
accomplished, but there are many aspects that are 
Figure 5 : miRNA database
Source: The miRNA Registry website
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not fully understood.
•  Elucidation of RNA interference (RNAi)
 mechanism
Some par ts  of  “the mechan ism of gene 
silencing mediated by double - stranded RNAs” 
described in Figure 1, such as the detai led 
structure of the RISC complex or its function, 
remain unclear. Further research is required to 
elucidate the details of the mechanism.
• The roles of small interference RNAs
 (miRNAs) in vivo
Recent studies reveal that a mammalian cell 
contains about 250 miRNAs, which are assumed 
to be controlling the expression of various genes 
in vivo.
These small interference RNAs (miRNAs) 
are assumed to be controlling the expression 
of genes in various steps of development and 
differentiation or in various organs.
Some miRNAs act as switches for turning on 
and off gene expression. While, some proteins 
have functions of “suppressing” other proteins 
in vivo. When the expression of genes for such 
proteins is suppressed by the miRNAs, the other 
proteins are freed from the “suppression” and 
regain their “expression.”
The elucidation of the functions of all 250 
miRNAs in a mammalian cell should lead to 
the elucidation of the in vivo  mechanism 
of gene regulation and the network among 
genes. However, most miRNAs have not been 
functionally identified.
• Relationship between suppression of gene
 expression and RNAi in chromosomes
A normal chromosome has regions where the 
expression of particular genes is suppressed by 
methylation. An unstable gene suppression status 
prevents normal development or differentiation 
or induces diseases such as cancer or congenital 
abnormality. Recent reports suggest that such 
chromosomal gene suppression involves an 
RNAi - mediated mechanism, but the actual 
mechanism is unknown.
The control of gene suppression status in 
chromosomes should provide novel findings 
in development and di f ferentiation studies 
and ultimately bring a breakthrough in the 
development of new drugs for treating diseases. 
It is therefore important to elucidate th is 
mechanism.
5-2 Unresolved research issues concerning
 the applied research toward medical
 application
Since RNAi drugs have not been developed, 
it is difficult to estimate the size of the market 
concerning drug development using RNAi. RNAi 
is currently applied mainly to experimental 
techniques or reagents for research, and its 
market size is estimated to be $300 million. 
Such techniques should be involved in the 
development of therapeutic drugs or techniques, 
so the current value of the drug development 
market using RNAi is estimated to be $500 
million. By 2010, the market is expected to 
increase to $1 billion[24].
Meanwhile, many research issues must be 
resolved before the practical application of RNAi 
to drugs.
• The issue of in vivo drug delivery system
 (DDS)
The drug delivery system (DDS) is an important 
issue for using siRNA as drugs. The siRNAs 
administered through ordinary means must be 
securely delivered to the target organs, stably exist 
in vivo until therapeutic effects are achieved and 
exert the effects in a sustained manner.
Some of the possible means for delivering 
the siRNAs in vivo are (1) the use of synthetic 
polymers such as liposomes as carriers or (2) the 
use of safe virus vectors as carriers. Such means 
have been discussed in gene therapy research, 
but sufficiently safe and efficient techniques have 
not been achieved.
Nanotechnology-based techniques such as the 
use of nanoparticles as carriers are promising 
DDS techniques that may be developed in the 
future.
• The issue of side effects
Highly selective drugs are thought to posses 
few side effects. However, even among the 
drugs recently developed as molecular-targeting 
drugs with few side effects, some drugs have 
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been reported to exert severe effects in certain 
patients. In the case of gene - targeted drugs, 
certain combinations of the drug and the genetic 
status of the patients may produce unexpected 
side effects.
Moreover, even though the human genome 
has been decoded, the overall network among 
genes and thei r functions in v ivo is fu l ly 
understood. This means that there is a risk that 
the suppression of a certain gene may induce 
unexpected suppression or expression of other 
genes.
In addition to mRNAs, cells contain small 
RNAs present within the nuclei involved in the 
biosynthesis of ribosomal RNAs. The RNAi drugs 
introduced into the cells may be transferred 
into the nuclei and bind to these small nuclear 
RNAs[25].
5-3 Research promoting medical application
 of gene silencing
Drugs based on gene silencing directly or 
indirectly acts against the genes. Therefore, 
their safe, effective use requires suff icient 
understanding of in vivo functions of the major 
genes, the regulator y mechanism of thei r 
expression and the network among genes.
The fol lowing research is suggested for 
understanding such subjects.
(1) Basic research using model organisms
The function of vital genes are common 
among all living organisms, so detailed studies 
using model organisms should provide results 
applicable to humans.
Extensive research has been conducted on 
experimental organisms such as nematodes 
and drosophila, but even in such organisms, 
little is understood regarding the vital functions 
responsible for life itself, including the genes.
(2)  Basic research applying problem-solving 
approaches
In order to promote the medical application of 
gene-silencing research, it is important to solve 
research problems that are created in applied or 
clinical studies. For this purpose, it is effective 
to conduct basic research tak ing problem 
identification and problem-solving approach.
(3)  Applied and clinical studies according to 
needs
The medical application of gene silencing 
requires in formation of the patient types, 
their needs and the suitabi l ity of the gene 
silencing-based treatment for individual cases.
Applied and clinical studies must reflect the 
needs from the actual clinical environment, 
which requires the establishment of a system for 
efficiently providing the researchers with medical 
information.
6 Conclusions
Finally, this section characterizes the gene 
silencing and suggests measures to be taken for 
further promotion of the area.
6-1 Characteristics of this area
The following three points characterize the 
research area.
•  The fusion of several research areas has
 promoted gene-silencing research
Gene silencing has grown rapidly over the past 
4 -5 years. The area has expanded through the 
fusion of several basic research areas such as DNA 
methylation and RNA-mediated gene suppression. 
The research targets were first limited to plants 
but were soon expanded to yeast and nematodes. 
Now the research subjects have shifted from mice 
and other mammals to human disease therapy.
• Transition of the research phase is quick
In most cases of biomedical research, the 
research phase has shifted from basic research 
to applied research and ultimately to clinical 
research. This shift of the research phase has 
been very rapid in gene silencing (Table 5).
• The U.S. leads the area, but the number
 of citations of papers by Japanese
 authors is increasing
Analysis of research papers concludes that the 
U.S. plays a leading role in this research area. 
However, the number of citations of papers by 
Japanese authors is increasing, which implies the 
expansion of scale of domestic gene-silencing 
research.
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Among the papers publ ished in the top 
journals having impact factors of 10 or higher 
in 2002 -2003,  papers involv ing Japanese 
researchers as principal investigators were 
mostly supported by relatively large, project-type 
research support systems such as “21st century 
COE (Ministry of Education, Culture, Sports, 
Sc ience and Technolog y),”  “Grant - i n - A id 
for Scientif ic Research on the Priority Area 
(Ministry of Education, Culture, Sports, Science 
and Technology),” “Grant- in -Aid for Scientific 
Research (S) (Ministry of Education, Culture, 
Sports, Science and Technology),” “Research 
for the Future Program ( JSPS),” “Exploratory 
Research for Advanced Technology Program 
( JST)” and “Rice Genome Research Program 
(Ministry of Agriculture, Forestry and Fisheries).”
6-2 Measures for further promoting
 the gene silencing
Measures for further promoting the gene 
silencing are discussed based on the characteristics 
of the area.
(1) Importance of basic research taking
 a problem-solving approach
 in a spiral-type research area
In gene - silencing research, breakthroughs 
that were derived from basic research have 
established the direction of the applied research 
toward medical application. To date, the advance 
in gene-silencing research has greatly contributed 
to the elucidation of life, but many functions and 
mechanisms remain unknown, especially the 
common mechanisms shared by all organisms. 
These include the regulation of gene expression 
in the development and differentiation processes.
Furthermore, the medical application of this 
technology requires the resolution of several 
research problems, which involves not only 
applied or clinical studies but also basic studies 
including the elucidation of gene networks.
The area of gene-silencing research does not 
fit a linear advance model of “basic research→ 
applied research→ clinical research” but fits a 
spiral advance model of “basic research→ applied 
research→ clinical research→ basic research
→ applied research→ clinical research→ ” or a 
braid-type model in which the area is advanced 
through intertwining of “basic research”, “applied 
research” and “clinical research”.
The area is currently approaching the end 
of the first spiral. It is essential to start basic 
research taking the problem identification and 
problem-solving approach forward to the second 
spiral.
(2)  Establishment of an environment
 promoting spontaneous adoption of
 research from other areas
As can be seen from the fact that the gene-silencing 
research started from the area of plant research, 
breakthroughs that expanded the research area 
were derived from the adoption of research from 
other areas. Therefore, it is important to establish 
an environment promoting information exchange 
between various research areas.
For example, a funding agency decides a 
subject for research adopting a task- solving 
approach and recruits about 10 research groups 
taking different approaches and belonging to 
different research areas. About twice a year, 
the agency hosts interim meetings where the 
research groups can exchange their results. The 
agency does not enforce joint research among the 
groups but only promotes information exchange.
Alternatively, it may be effective to organize 
a research meeting for researchers gathered 
from various areas. As in the Gordon Research 
Conference, the participants selected by the 
committee congregate together and thoroughly 
debate a particular research issue in a closed 
environment.
Table 5 : Research phases in gene silencing research
Research phase Year Period Research subject
The first report 1990 (8 years) The first report on gene silencing
Basic research 1998 – 2001 4 years Elucidation of in vivo mechanism of gene silencing
Applied research 2002 – 2004 3 years Research using animal disease models toward medical application
Clinical research 2005 – ? ? Research concerning clinical trials performed on patients 
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